develop cGVHD de novo. Clinical presentation of chronic disease differs from the acute in that it resembles collagen vascular disease which is associated with significant morChronic graft-versus-host disease (cGVHD) is a disease of immune dysregulation that resembles an autoimmune bidity post-BMT. 3 The introduction of GVHD prophylaxis which combines T cell depletion 4 with post-transplant disease. It usually involves the skin, mucosal and serosal surfaces and, less commonly, the hematopoietic system.
but may also have changed its presentation. Although the mismatched related donor transplants. Five of 40 eligible patients developed HA at a median of 168 days association between cGVHD and thrombocytopenia is well documented, [7] [8] [9] [10] few cases of other immunohematologic post-transplant. Recipients were mismatched for one to three major HLA antigens. Conditioning therapy concomplications post-BMT have been described. [11] [12] [13] [14] [15] In this study, we report a presumably immune-mediated hemolytic sisted of total body irradiation, etoposide, Ara-C, cyclophosphamide and steroids. GVHD prophylaxis included anemia (HA) as the principal manifestation of cGVHD in patients following partially mismatched related donor partial T cell depletion, using anti ␣/␤ CD3 antibody (T10B9) and complement, in addition to post-transplant (PMRD)-BMT, discuss its possible mechanism, and emphasize the importance of early intervention with immunosuppression. At presentation, all patients were receiving cyclosporine with or without low-dose sterimmunosuppressive therapy. oids. Along with a mean Hb of 7.1g%, patients had an increased reticulocyte count, a mild raised lactic dehydrogenase and a positive Coombs' test (in 2/5 patients). Four patients had also demonstrated a Material and methods decrease in platelet count. Treatment was initiated with high-dose steroids and intravenous gamma globulin and response was observed within 1 week.
Awareness of this
Patients and clinical protocol presentation of cGVHD and early therapeutic intervention can result in successful reversal of presumed
In this retrospective analysis 40 consecutive patients who survived beyond 120 days following PMRD-BMT for hemimmune-mediated red cell and platelet destruction. Keywords: chronic graft-versus-host disease; hemolytic atological malignancies or marrow failure disorders were evaluated for cGVHD. Pre-transplant conditioning therapy anemia; bone marrow transplantation; T cell depletion; thrombocytopenia included TBI and high-dose chemotherapy combining etoposide (not given to marrow failure patients), Ara-C, cyclophosphamide and steroids, as previously describe. 16 Marrow grafts were T cell depleted by incubation with an antiChronic graft-versus-host disease (cGVHD) occurs in more ␣/␤ TCR T10B9.1A-31 monoclonal antibody (provided by than 50% of long-term survivors of BMT and is thought to John Thompson, University of Kentucky, under a FDA be due to proliferation of mature donor T cells in response approved IND for investigational use) and baby rabbit to host allo-antigens. Risk factors are HLA disparity, acute complement. 17 Additional GVHD prophylaxis included GVHD (aGVHD), older host age, and male recipients of post-transplant immunosuppression using cyclosporine grafts from alloimmune female donors.
1,2 Symptoms (levels maintained between 113 and 168 ng/ml whole blood develop most commonly immediately following aGVHD or using a monoclonal antibody assay), a course of antithymoafter a quiescent period, and only 20% of patients will cyte-globulin (10 mg/kg on day +5 to +16) and methylprednisolone (30 mg/m 2 daily until after day +16 with a subsequent taper of 10% weekly). Patients' complete blood Data collection ited involvement. Of those developing cGVHD, five patients (28%) presented with HA, with or without thromPatients' charts were reviewed for demographics, complibocytopenia on days 112-272 (median 168) post-transplant cations following BMT, occurrence of acute and chronic (Table 1) . Patients with HA were HLA mismatched with GVHD, diagnosis and treatment of anemia and response to their donors for one antigen (n = 1), two antigens (n = 3) treatment. Referring institutions were contacted when and three antigens (n = 2) and were all sex mismatched. patients were treated locally.
The donors were mothers for three patients, and a father or sister for one patient each. Four patients were ABO comEvaluation of hemolytic anemia patible with their donors but had a variety of minor antigen mismatches. None of the patients developed aGVHD within HA was suspected when an acute fall in hemoglobin 3 months of BMT, however, all reported limited skin manioccurred in a patient who had otherwise stable engraftment, festations of cGVHD that were visible at the time of diagwas transfusion independent, and had no evidence of blood nosis of HA. loss. Patients were evaluated using the following tests: perAt time of presentation, hematologic findings included a ipheral blood cell morphology, reticulocyte count, lactic mean Hb level of 7.1g%, reticulocyte count of 10.7% dehydrogenase (LDH), haptoglobin, direct and indirect (range 5.8-12.9%), a peripheral blood smear free from eviCoomb's test and platelet antibodies, when available. For dence of microangiopathy, elevated LDH in 3/5 patients the Coombs' (direct antiglobulin) test, patients' red cells (Table 2) and Coombs' test positive in 2/5 patients (direct were incubated with a polyspecific antiglobulin reagent. In in two patients and indirect in one). No specificity to red patients whose Coombs' test was positive, cells were eluted cell antigen was demonstrated in the direct (following and further testing was done with a panel of antibodies elution) or indirect Coombs' positive patients. Haptoglobin directed against human immunoglobulins or complement was measured in two patients (CS and CK) and was found component, to determine specificity. Indirect Coombs' was to be low. In addition to a decline in hemoglobin level, 4/5 performed by incubating patients' sera with pooled patients presented with a decrease in their platelet count to screened red cells. As most of the patients were back at a median of 50 000/mm 3 (range from 3000-141 000). In one their referring institutions, data on further characterization patient (CK), platelet antibody was tested and found to be of the hemolysis was not always available. Appropriate weakly positive. investigations were performed to exclude the possibility All five patients had been maintained on GVHD prophyof infection.
laxis with cyclosporine; however, four were taken off steroid therapy within 2 weeks prior to presentation. Treatment Immunophenotype analysis by flow cytometry of HA was initiated with pulse high dose steroids (500-Peripheral blood was routinely collected from donors prior 1000 mg/kg × 2 doses) and daily intravenous gammato BMT and from patients pre-BMT and on days +14, +28, globulin × 3-5 doses and continued as shown in Table 3 . +60, +100 and +180. The cells were stained with MAbs to
Response was observed in 4/5 patients within 1 week and the T lymphocyte markers CD3, CD4, CD8, TCR-␣␤, and complete recovery that allowed tapering of therapy within TCR-␥␦; the natural killer markers CD16, CD56, and 4 weeks. However, one of these patients (DH) required re-CD57; the B lymphocyte marker CD19; the activation martreatment for a transient recurrence of HA. In the remaining kers CD25, IL-2Rp75, and HLA-DR, and IgG 1 and IgG 2a patient (HR), delay in diagnosis and treatment was associacontrol MAbs conjugated with the appropriate fluoroted with a slow response (3 weeks) and the need for conchrome. MAbs were obtained from Becton Dickinson tinuous high-dose intensive immunosuppressive therapy Immunocytometry Systems (BDIS, San Jose, CA, USA), using four drugs (pulse high-dose steroids, IVIG, cyclospoexcept for anti-TCR-␣␤ which was obtained from T Cell rine and azathioprine). Three patients continued to manifest Diagnostics (Cambridge, MA, USA).
limited skin cGVHD symptoms once immunosuppressants When the peripheral WBC count was less than were tapered and had to be maintained on cyclosporine 0.5 × 10 6 /ml, flow cytometric analysis was performed on alternating with low-dose steroids. HA was within the observed range for non-affected patients lysis using FACS-Lyse from BDIS. Cells were stained as post PMRD-BMT, and thus no association was seen described previously. 18 At least 10 000 events were colbetween the distribution of lymphocyte subsets and the lected on a Becton Dickinson FACSort flow cytometer. Cell development of HA or thrombocytopenia (Figure 1 ). All subpopulations in the lymphocyte scatter gate were quantitpatients became full donor hematopoietic chimeras by ated and normalized to the actual percentage of lymphocyte RFLP, and remain in hematological remission from their events within this gate using Lysis II software. Cell subpopprimary malignancy between 17 and 32 months post-transulation percentages were expressed as a percentage of the plant. total lymphocyte population.
Discussion Results

Eighteen of 40 (45%) eligible patients following PMRD-
In this retrospective study we reported on HA, a relatively uncommon manifestation of cGVHD, 3 as a major manifes-BMT developed cGVHD, most of them (15/18) with lim- HD-MPD = methylprednisolone 500-1000 mg/m 2 followed by prednisone 0.5-2 mg/kg; TIW = three times a week; w = week; BIW = twice weekly; qod = every other day; qow = every other week. tation of the disorder among patients who received T cellalthough the disorder was also described in patients post-BMT who did not receive the medication. 21 None of our depleted PMRD-BMT. HA, often accompanied by thrombocytopenia, presented de novo in approximately one-third patients developed renal insufficiency (data not shown), hypertension or any other clinical or morphologic manifesof patients who developed cGVHD. Patients had no history of aGVHD and had otherwise limited skin manifestation of tation of thrombotic microangiopathy. The mechanism of immune HA post-BMT is not comthe disorder. Risk factors that may have contributed to the development of cGVHD in our patients included HLA displetely understood, although several investigators have suggested that T cell suppression may lead to predominance of parity, both known major and unknown minor HLA differences, and sex mismatched donor-recipient pairs. Never-B cell function, resulting in production of auto-antibodies. Hazelhurst et al, 22 speculated that enhanced B cell activity theless, our patients did not have other risk factors including aGVHD and older age as previously reported in secondary to lack of CD8 T cell suppression was the cause of the HA in nine recipients of T cell-depleted marrows. Others have suggested that cyclosporine post-transplant may permit antibody formation due to its selective effect test and platelet antibody, when tested) all patients responded to intensive immunosuppressive therapy.
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on T cell function with sparing of B cells. 23 In our study, we were not able to demonstrate a difference in B cell number Other conditions that may give rise to HA post-BMT include infection or medication. Our patients maintained between patients who developed HA and those who did not, and moreover, B cell recovery in all post-PMRD-BMT stable engraftment with no evidence of recurrent disease or infection. Other than cyclosporine, patients did not receive patients was relatively delayed compared to that reported in recipients of HLA-matched BMT (following both T cellmedications known to cause HA. Cyclosporine is reported to be associated with hemolytic-uremic syndrome, 20 depleted and non-depleted grafts). As to the origin of the cells causing immune-mediated was part of pancytopenia of immune etiology post-BMT. 12, 14 The reason for the high prevalence of HA in HA, persistence of residual host cells may produce antibodies directed against the newly developed donor red patients post-PMRD-BMT is unknown, however, factors such as T cell depletion or its methodology may play a cells. This usually occurs in the early post-transplant period and accounts for the HA seen in ABO mismatch. 23, 25 Most role. Recent data from our center show that using a different antibody (OKT3) for T cell depletion, has not been of our patients were ABO compatible and, although they all had different minor group incompatibilities, those are associated with HA. As more patients receive grafts which are HLA disparate, not usually associated with hemolysis. Immune HA may also occur as a consequence of a mixed hematopoietic referring and transplant physicians need to increase awareness for HA as a late complication of BMT. Recognition chimera where donor antibodies are formed against recipient hematopoietic cells. This is unlikely to be the mechof HA post-BMT, followed by prompt and aggressive immunosuppressive therapy is important in achieving conanism in our patient population, since all of them were full donor hematopoietic chimeras by cytogenetic analysis and trol of red cell and platelet destruction; waiting for additional laboratory findings before establishing treatment RFLP with no evidence of residual hematopoietic host cells.
may interfere with timely and effective therapy. Finally, post-transplant immune system dysregulation, whereby donor cells triggered by host tissue produce antiAcknowledgements bodies against the engrafted hematopoietic system, giving rise to an 'auto'-immune (donor-anti-donor) HA, is consistWe wish to thank Ms Jan Cannon and Ms Gail Wingo for their ent with the concept of cGVHD as an autoimmune disassistance in data collection and Ms Joan Parnell for her assistance order. 3 The relatively infrequent detection of antibodies in preparation of the manuscript.
(Coombs' test) in our patients could be related to low numbers of B cells resulting in a low production level of an aberrant antibody. This antibody is rapidly adsorbed and References the formed antibody-coated red blood cells are instantly destroyed. Although immune thrombocytopenia post-BMT maternal donors). 11 In the other two reported patients, HA
